Molecular Templates to Present at Upcoming Investor Conferences
May 17, 2022 16:05 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
May 12, 2022 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach
April 12, 2022 07:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, April 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors
April 08, 2022 08:00 ET
|
Molecular Templates, Inc.
Event will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am ET AUSTIN, Texas, April 08, 2022 (GLOBE...
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
March 28, 2022 16:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Strengthens Board of Directors and Management Team
March 02, 2022 08:00 ET
|
Molecular Templates, Inc.
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:...
Molecular Templates to Present at the Upcoming Investor Conferences
March 01, 2022 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
November 30, 2021 17:30 ET
|
Molecular Templates, Inc.
Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in...
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
November 18, 2021 08:00 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
November 15, 2021 07:30 ET
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...